Eisai Co., Ltd. (ESALF)

38.71 0.00 (0.00%) At close: 11:05AM EDT

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 11,076

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Haruo Naito	CEO, Representative Corporate Officer & Director	N/A	N/A	1947
Mr. Gary Hendler	Senior VP & President of EMEA Region	N/A	N/A	1966
Dr. Lynn D. Kramer FAAN, M.D.	Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain Health	N/A	N/A	1950
Ms. Yanhui Feng	Senior Vice President	N/A	N/A	1972
Dr. Nadeem Sarwar Ph.D.	President	N/A	N/A	N/A
Mitsuru Shomon	VP & CFO	N/A	N/A	N/A
Mr. Yasushi Okada	Representative Corporate Officer, COO, Industry Affairs, China Business & Data Integrity	N/A	N/A	1958
Makoto Hoketsu	VP & Chief Information Officer	N/A	N/A	N/A
Mr. Masatomi Akana	Chief Gov. Rel. and IR Officer, SVP of Global Value, Acc., Japan Subs, General, Env. & Safety Aff.	N/A	N/A	1967
Mr. Kenta Takahashi	Executive VP of IP, Internal Audit & Control, General Counsel and Chief Compliance Officer	N/A	N/A	1959

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Corporate governance

Eisai Co., Ltd.’s ISS governance QualityScore as of 1 April 2024 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 6; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.